TROMLIEVA 25 mg contains Eltrombopag Olamine, an oral thrombopoietin (TPO) receptor agonist. It stimulates platelet production by activating the c-Mpl receptor on megakaryocyte precursors in the bone marrow, leading to increased platelet counts.

Eltrombopag is used for:

1. Chronic Immune (Idiopathic) Thrombocytopenia (ITP)
     – In patients with inadequate response to corticosteroids, IVIG, or splenectomy

2. Severe Aplastic Anemia
     – Refractory cases or in combination with immunosuppressive therapy

3. Thrombocytopenia associated with Chronic Hepatitis C
     – To allow initiation and maintenance of interferon-based therapy (where applicable)

Common side effects:

•  Headache

•  Nausea, diarrhea

•  Fatigue

•  Increased liver enzymes

Serious side effects:

•  Hepatotoxicity

•  Thromboembolic events

•  Cataract formation (long-term use)

•  Bone marrow fibrosis (rare)

Liver function tests and platelet counts must be monitored regularly.

Dosage is individualized based on platelet response and indication.

Typical dosing:

•  25 mg once daily (especially in East Asian patients or those with hepatic impairment)

•  Dose may be increased gradually (up to 50–75 mg/day) based on platelet count

25 mg strength is commonly used as a starting or maintenance dose.


NOTE: This medicine should be taken only under a doctor’s supervision.